Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Total Non-Current Liabilities: 2011-2019

Historic Total Non-Current Liabilities for Niagen Bioscience (NAGE) over the last 6 years, with Dec 2019 value amounting to $19.6 million.

  • Niagen Bioscience's Total Non-Current Liabilities fell 30.73% to $20.2 million in Q2 2020 from the same period last year, while for Jun 2020 it was $20.2 million, marking a year-over-year decrease of 30.73%. This contributed to the annual value of $19.6 million for FY2019, which is 32.84% up from last year.
  • Per Niagen Bioscience's latest filing, its Total Non-Current Liabilities stood at $19.6 million for FY2019, which was up 32.84% from $14.8 million recorded in FY2018.
  • Niagen Bioscience's Total Non-Current Liabilities' 5-year high stood at $19.6 million during FY2019, with a 5-year trough of $8.6 million in FY2017.
  • For the 3-year period, Niagen Bioscience's Total Non-Current Liabilities averaged around $14.3 million, with its median value being $14.8 million (2018).
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first fell by 28.89% in 2016, then soared by 72.33% in 2018.
  • Yearly analysis of 4 years shows Niagen Bioscience's Total Non-Current Liabilities stood at $13.2 million in 2016, then decreased by 28.89% to $9.4 million in 2016, then declined by 8.66% to $8.6 million in 2017, then skyrocketed by 72.33% to $14.8 million in 2018, then skyrocketed by 32.84% to $19.6 million in 2019.